Everolimus (RAD001): Orally Bioavailable mTOR Inhibitor for Cancer Research

Executive Summary: Everolimus (RAD001) is a potent, orally bioavailable mTOR pathway inhibitor that acts via FKBP12 complex formation and subsequent mTOR kinase inhibition, resulting in decreased phosphorylation of S6K1 and 4EBP, and suppression of cancer cell proliferation (Schwartz 2022). APExBIO supplies Everolimus (A8169) for research applications, ensuring high purity and stability (APExBIO product page). Everolimus exhibits notable in vitro activity in Panc-1 (IC50 = 50 μg/mL) and ScLc (IC50 = 5 μg/mL) cell lines, although these concentrations exceed typical therapeutic serum levels. The compound is highly soluble in DMSO and ethanol, but insoluble in water, affecting assay design. In vivo, it suppresses tumorigenesis in animal models, including ovarian cancer, and is employed broadly in apoptosis and cell proliferation research workflows.

Biological Rationale

The mTOR pathway is central to cell growth, proliferation, and survival. Dysregulation of the PI3K/Akt/mTOR axis is implicated in multiple human cancers (Schwartz 2022). Targeting mTOR can suppress aberrant cell proliferation and induce apoptosis in cancer cells. The need for selective, cell-permeable mTOR inhibitors has driven the adoption of Everolimus (RAD001) in cancer biology research. Its oral bioavailability enables systemic administration in animal models, facilitating translational studies. Everolimus is routinely used in apoptosis assays and cancer cell proliferation inhibition experiments.

Mechanism of Action of Everolimus (RAD001)

Everolimus binds with high affinity to the intracellular receptor FKBP12. This complex then associates with mTOR, a serine/threonine kinase crucial for integrating growth factor and nutrient signals. Binding of the Everolimus-FKBP12 complex to mTOR inhibits its kinase activity. This results in decreased phosphorylation of downstream effectors such as S6K1 (ribosomal protein S6 kinase) and 4EBP (eukaryotic initiation factor 4E-binding protein) (Schwartz 2022). The net effect is downregulation of protein synthesis and inhibition of cell cycle progression, ultimately reducing cancer cell proliferation. Everolimus is classified as a cell-permeable mTOR pathway inhibitor, suitable for both in vitro and in vivo research.

Evidence & Benchmarks

• Everolimus demonstrates antiproliferative effects in Panc-1 pancreatic tumor cells (IC50 = 50 μg/mL, 72 h incubation, standard culture conditions) (Schwartz 2022, Table 2.1).
• In ScLc small cell lung cancer cells, Everolimus inhibits proliferation with an IC50 of 5 μg/mL (72 h, 37°C, 5% CO₂) (Schwartz 2022, Table 2.1).
• Therapeutic serum levels in clinical contexts are typically 0.005–0.01 μg/mL, below in vitro IC50 values, indicating context-dependent efficacy (Schwartz 2022, Section 2.2).
• Everolimus is highly soluble in DMSO (≥47.91 mg/mL) and ethanol (≥122 mg/mL), but insoluble in water, impacting formulation and delivery (APExBIO).
• In the TgMISIIR-TAg-DR26 mouse model of ovarian cancer, Everolimus effectively suppresses tumorigenesis (in vivo efficacy, administration via oral gavage, 5 mg/kg) (Schwartz 2022, Section 3.1).

This article extends prior coverage in "Precision mTOR Inhibitor Workflows in Cancer Models" by providing quantitative benchmarks and clarifying solubility and dosing limitations. For further mechanistic details, see "Mechanisms and Advanced Applications", which this article updates with latest in vivo data. More on workflow integration is discussed in "Orally Bioavailable mTOR Inhibitor for Apoptosis and Proliferation Assays", but herein, precise formulation and storage protocols are emphasized.

Applications, Limits & Misconceptions

Everolimus (RAD001) is widely used in:

• Apoptosis assays in cancer cell lines (e.g., Panc-1, ScLc).
• Cancer cell proliferation inhibition studies.
• Renal cell carcinoma and ovarian cancer animal models.
• Dissecting signal transduction in the PI3K/Akt/mTOR pathway.
• Evaluating resistance mechanisms to mTOR inhibition.

Common Pitfalls or Misconceptions

• IC50 values in vitro do not equate to clinically relevant dosing. Typical in vitro IC50s are orders of magnitude higher than therapeutic serum concentrations, so translational assumptions must be carefully validated (Schwartz 2022).
• Water insolubility limits aqueous formulation. Everolimus must be dissolved in DMSO or ethanol for in vitro and in vivo applications; improper solubilization may lead to precipitation and inconsistent dosing (APExBIO).
• Not all mTOR pathway effects are due to direct mTOR inhibition. Off-target effects or pathway cross-talk may confound readouts; proper controls are essential (Schwartz 2022).
• Degradation upon improper storage. Everolimus solutions degrade at room temperature; storage below -20°C is required for stability (APExBIO).
• Misinterpretation of apoptosis versus proliferation endpoints. Relative viability does not distinguish between cytostatic and cytotoxic effects; fractional viability assays are recommended (Schwartz 2022).

Workflow Integration & Parameters

For in vitro studies, Everolimus is typically dissolved in DMSO or ethanol to prepare stock solutions (≥47.91 mg/mL in DMSO, ≥122 mg/mL in ethanol). A working concentration range of 1–100 μg/mL is used for most cancer cell assays, depending on cell type and endpoint (Schwartz 2022). For in vivo applications, oral gavage is preferred, with dosing regimens adapted from published studies (e.g., 5 mg/kg in mouse models). Stock solutions should be stored below -20°C and used within several months to prevent degradation. APExBIO provides Everolimus (A8169) with detailed handling instructions (product page).

Conclusion & Outlook

Everolimus (RAD001) is a robust, well-characterized mTOR inhibitor enabling precise dissection of the PI3K/Akt/mTOR pathway in cancer research. Its proven antiproliferative and pro-apoptotic effects are supported by quantitative benchmarks in established models. Researchers should be mindful of solubility, dosing, and assay selection to maximize reproducibility and translational relevance. For comprehensive protocols and troubleshooting, consult APExBIO resources and recent methodological reviews (APExBIO; Schwartz 2022).